About
Alzheimer's Treatment
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
6,658
By Phase
PHASE4: 3PHASE3: 1
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 1SUSPENDED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05908695Lead Sponsor
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
PHASE4Recruiting
1,312 participants
Started: Aug 31, 2023 · Completed: Dec 31, 2029
NCT05181475Lead Sponsor
Long-term Efficacy and Safety Study of GV-971
PHASE4Active, not recruiting
800 participants
Started: Dec 7, 2021 · Completed: Jun 30, 2025
NCT05058040Lead Sponsor
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
PHASE4Active, not recruiting
2,500 participants
Started: Jun 2, 2021 · Completed: Apr 30, 2025
NCT04520412Lead Sponsor
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
PHASE3Suspended
2,046 participants
Started: Oct 27, 2020 · Completed: Oct 31, 2026
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...